SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

CDT Equity Inc. CDT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

CDT Equity Inc. (CDT) is a Biotechnology company in the Healthcare sector, currently trading at $4.77. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 1 out of 7 criteria passed.

Valuation: CDT trades at a trailing Price-to-Earnings (P/E) of 0 (S&P 500 average ~25).

Financials: revenue is $2.7B, +194.4%/yr average growth. Net income is $238M, growing at +12433%/yr. Net profit margin is 8.7% (thin). Gross margin is 38% (-62 pp trend).

Balance sheet: total debt is $1.3B against $1.3B equity (Debt-to-Equity (D/E) ratio 1.02, moderate). Current ratio is 1.93 (strong liquidity). Debt-to-assets is 36.3%. Total assets: $3.5B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 50/100 (Partial), Health 67/100 (Partial), Moat 33/100 (Fail), Future ?/100 (Fail), Income 45/100 (Partial).

CDT SharesGrow Score Overview

59/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 50/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 33/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CDT

No analyst coverage available for this stock.

CDT: +194.4%/yr revenue is, +12433%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CDT: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CDT: Debt-to-Equity (D/E) ratio 1.02 (moderate), Current ratio is 1.93 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CDT: Gross margin is 38% (-62 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 33/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

CDT: Net profit margin is 8.7%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range3.83-4200

Volume28.75K

Avg Volume (30D)74.89K

Market Cap$843.52K

Beta (1Y)2.08

Share Statistics

EPS (TTM)1,500.00

Shares Outstanding$158.42K

IPO Date2022-03-28

Employees6

CEOAndrew Regan

Financial Highlights & Ratios

Revenue (TTM)$2.72B

Gross Profit$1.03B

EBITDA$315.69M

Net Income$237.52M

Operating Income$315.69M

Total Cash$389.89M

Total Debt$1.29B

Net Debt$895.78M

Total Assets$3.54B

Price / Earnings (P/E)0

Price / Sales (P/S)0

Analyst Forecast

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS20678X5023

Price Chart

CDT

CDT Equity Inc. ↗ · NASDAQ Global Market

Healthcare • Biotechnology

3.83 52WK RANGE 4,200.00

People Also View

Envoy Medical, Inc.

Lixte Biotechnology Holdings, Inc.

ZyVersa Therapeutics, Inc.

NewGenIvf Group Limited

Enveric Biosciences, Inc.

Concord Medical Services Holdings Limited

Hepion Pharmaceuticals, Inc.

Longevity Health Holdings Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message